China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical development of its TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, ICP-488, with the dosing of the first psoriasis patient in China. This marks a progressive step towards addressing the treatment needs for psoriasis and other autoimmune diseases.
ICP-488: A Selective TYK2 Allosteric Inhibitor
ICP-488 is a potent and selective TYK2 allosteric inhibitor that is being developed to treat psoriasis and other autoimmune diseases. It works by blocking the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines through binding to the JH2 domain. This mechanism inhibits the pathological processes associated with autoimmune and inflammatory diseases, offering a potential new therapeutic approach.
Clinical Progression of InnoCare’s Autoimmune Pipeline
ICP-488 is InnoCare’s third autoimmune disease drug to reach the clinical trial stage, following the initiation of a clinical study for an autoimmune disease in August 2022. The company’s commitment to advancing treatments for autoimmune conditions is evident in its ongoing clinical research and development efforts.-Fineline Info & Tech
